Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Capital Expenditures (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Capital Expenditures for 5 consecutive years, with $11000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Capital Expenditures fell 85.53% to $11000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $11000.0, a 92.81% decrease, with the full-year FY2024 number at $11000.0, down 92.81% from a year prior.
  • Capital Expenditures was $11000.0 for Q1 2024 at Actinium Pharmaceuticals, down from $30000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $270000.0 in Q2 2022 to a low of $4000.0 in Q1 2021.
  • A 4-year average of $60272.7 and a median of $47000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 985.71% in 2023, then crashed 85.53% in 2024.
  • Actinium Pharmaceuticals' Capital Expenditures stood at $68000.0 in 2021, then crashed by 76.47% to $16000.0 in 2022, then surged by 87.5% to $30000.0 in 2023, then plummeted by 63.33% to $11000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Capital Expenditures are $11000.0 (Q1 2024), $30000.0 (Q3 2023), and $47000.0 (Q2 2023).